Medtech Deals In Depth: February 2022
Executive Summary
CooperCompanies' acquisition of Cook Group’s reproductive health business for $875m was the only blockbuster medtech/diagnostics deal in February.
You may also be interested in...
Deals In Depth: February 2022
Five $1bn+ alliances were penned in February. Topping the list was a potential $2bn deal between Code Biotherapeutics and Takeda to leverage Code Bio’s proprietary targeted 3DNA non-viral genetic medicine delivery platform to design and develop gene therapies for a liver-directed rare disease program, plus central nervous system-directed rare disease programs. Takeda has the right to exercise options for an exclusive license for four resulting programs.
Deals Shaping The Medical Industry, February 2022
In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2022. Data provided by Biomedtracker.
Deals Shaping The Medtech Industry, January 2022
Medtech Insight's Deal Making column is a survey of recent health care transactions listed by relevant industry segment – in vitro diagnostics and medical devices – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2022. Data provided by Biomedtracker.